Companies Pretzel Therapeutics

Pioneering mitochondrial therapies


Dysfunctional mitochondria (the source of energy for most cells) are involved in more than 50 diseases; rare genetic conditions and much more common disorders, such as heart disease and Parkinson’s disease.

Today, there are no therapies for many of these diseases. Pretzel Therapeutics is developing a novel pipeline of drugs to modulate mitochondrial biology and generate therapies for a wide range of high unment need diseases.

Cambridge Innovation Capital is a leading Series A investor in the Cambridge ecosystem.

We were born out of a unique relationship with the University of Cambridge and we maintain privileged access to its most inspiring ideas and people in life sciences and deep tech.

Discover more


Read More